Volume : 13, Issue : 04, April – 2026

Title:

GABAPENTIN INDUCED ACUTE ENCEPHALOPATHY IN A 68 YEAR OLD MALE TREATED FOR POST – HERPETIC NEURALGIA

Authors :

Somasani Jyoshna*, Palle Umamaheshwari, C Rakesh Kumar, D.Goutham

Abstract :

Gabapentin is widely used in the management of neuropathic pain and is generally considered safe[1]. However, in rare cases, it may lead to serious neurological adverse effects such as acute encephalopathy, particularly in elderly patients[2]. We present the case of a 68-year-old male who developed sudden confusion, disorientation, and excessive drowsiness shortly after starting gabapentin for post-herpetic neuralgia[3]. Clinical evaluation and laboratory investigations, including renal and liver function tests, were within normal limits[4]. Neuroimaging showed no abnormalities, while electroencephalography revealed diffuse slowing suggestive of encephalopathy[5]. Gabapentin was discontinued, and the patient showed marked improvement within 48 hours, with complete recovery by 72 hours[6]. This case highlights the importance of early recognition of drug-induced neurological adverse effects and the need for cautious use of gabapentin in elderly patients[7].
Keywords : Gabapentin , Acute encephalopathy , Adverse drug reaction , Neurotoxicity .

Cite This Article:

Please cite this article in press Somasani jyoshna et al., Gabapentin Induced Acute Encephalopathy In A 68 Year Old Male Treated For Post – Herpetic Neuralgia, Indo Am. J. P. Sci, 2026; 13(04).

REFERENCES:

1. Rose MA, Kam PC. Gabapentin: pharmacology and its use in pain management. Anaesthesia. 2002;57(5):451-462.
https://pubmed.ncbi.nlm.nih.gov/11966552/
2. Zand L, McKian KP, Qian Q. Gabapentin toxicity in patients with chronic kidney disease: a preventable cause of morbidity. Am J Med. 2010;123(4):367-373.
https://pubmed.ncbi.nlm.nih.gov/20362760/
3. Wills BK, Reynolds PM, Chu E. Clinical outcomes in newer anticonvulsant overdose: a poison center observational study. J Med Toxicol. 2014;10(3):254-260.
https://pubmed.ncbi.nlm.nih.gov/24619543/
4. Mersfelder TL, Nichols WH. Gabapentin: abuse, dependence, and withdrawal. Ann Pharmacother. 2016;50(3):229-233.
https://pubmed.ncbi.nlm.nih.gov/26721643/
5. Kaplan PW. EEG criteria for nonconvulsive status epilepticus. Epilepsia. 2007;48(Suppl 8):39-41.
https://pubmed.ncbi.nlm.nih.gov/18304252/
6. Friedman JH, Factor SA. Atypical antiepileptic drug toxicity in the elderly. Drugs Aging. 2000;16(5):353-360.
7. By the American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2019 Updated Beers Criteria®. J Am Geriatr Soc. 2019;67(4):674-694.
https://pubmed.ncbi.nlm.nih.gov/30693946/
8. Taylor CP, Gee NS, Su TZ, et al. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res. 1998;29(3):233-249.
https://pubmed.ncbi.nlm.nih.gov/9578047/
9. Field MJ, Cox PJ, Stott E, et al. Identification of the α2δ subunit as a target for gabapentin. Proc Natl Acad Sci USA. 2006;103(46):17537-17542.
https://pubmed.ncbi.nlm.nih.gov/17088553/
10. Chouinard G, Beauclair L, Belanger MC. Gabapentin-induced delirium. J Clin Psychopharmacol. 1998;18(6):481-482.
https://pubmed.ncbi.nlm.nih.gov/9864086/
11. Mangoni AA, Jackson SH. Aging and pharmacology. Br J Clin Pharmacol. 2004;57(1):6–14.
https://pubmed.ncbi.nlm.nih.gov/14678335/
12. Aronoff GR, et al. Drug prescribing in renal failure. Am J Kidney Dis. 2007;49(1):A7–A9.
https://pubmed.ncbi.nlm.nih.gov/17185147/
13. Goodman CW, Brett AS. Gabapentin and pregabalin for pain. N Engl J Med. 2017;377:411–414.
https://pubmed.ncbi.nlm.nih.gov/28767349
14.Naranjo CA, et al. A method for estimating probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245.
https://pubmed.ncbi.nlm.nih.gov/7249508/
15. Farrall AJ, Wardlaw JM. Blood–brain barrier in aging. Neurobiol Aging. 2009;30(3):337–352.
https://pubmed.ncbi.nlm.nih.gov/17869382/
16. Löscher W, Potschka H. Role of BBB in drug transport. Epilepsia. 2005;46(Suppl 1):22–32.
https://pubmed.ncbi.nlm.nih.gov/15816976
17. Hanlon JT, et al. Polypharmacy in elderly. J Am Geriatr Soc. 2001;49(3):284–289.
https://pubmed.ncbi.nlm.nih.gov/11300241/
18.Adams RD, Victor M. Principles of Neurology. McGraw-Hill; standard reference.
19. Young GB. EEG in encephalopathy. J Clin Neurophysiol. 2000;17(5):473–483.
https://pubmed.ncbi.nlm.nih.gov/11012042/
20. Zaccara G, et al. Clinical adverse effects of antiepileptics. CNS Drugs. 2007;21(8):633–653.
https://pubmed.ncbi.nlm.nih.gov/17696574/
21. Tatum WO. Clinical approach to encephalopathy. Neurol Clin. 2011;29(1):1–14.
https://pubmed.ncbi.nlm.nih.gov/21109158/